Imiquimod (R 837，咪喹莫特) - 仅供科研 | TLR7 Agonist | MCE
Imiquimod (R 837) 是一种 toll 样受体7 (TLR7) 激动剂，作为一种免疫反应修饰剂。 Imiquimod 在体内表现出抗病毒和抗肿瘤作用。 Imiquimod 可用于外生殖器、肛周疣、癌症和 COVID-19 …
Extracellular miRNAs induce potent innate immune responses
2017年9月9日 · Bone marrow-derived macrophages (BMDM) were isolated from wild-type and genetically modified mice and treated with various lipofectamine-complexed miRNA mimics …
TLR7 gain-of-function genetic variation causes human lupus
2022年4月27日 · We show that enhanced TLR7 signalling drives aberrant survival of B cell receptor (BCR)-activated B cells, and in a cell-intrinsic manner, accumulation of CD11c + age …
TfR-T12 short peptide and pH sensitive cell ... - ScienceDirect
2022年4月1日 · It was found that the addition of R837 could induce a large amount of TNF-α release from BMDM cells, while TfR/TATH7/PTX/R837 NMs (pH 5.5) could also induce the …
The TLR7 agonists imiquimod and gardiquimod improve DC …
2010年6月14日 · In this study, we demonstrate that both gardiquimod and imiquimod promote the proliferation of murine splenocytes, stimulate the activation of splenic T, NK and natural killer T …
Cardiac RNA Induces Inflammatory Responses in Cardiomyocytes …
2015年10月10日 · Bone marrow-derived macrophages (BMDM) were isolated from wild-type (WT) and genetically modified mice, and treated with Lipofectamine-complexed RNA (10 μg/ml), …
European Journal of Immunology - Wiley Online Library
In the human system poly IC served as a TLR3 agonist, whereas R848 was replaced by R837 (a strictly TLR7 ligand), as human BDCA1 + DCs express TLR8 that could be triggered by R848 …
咪喹莫特 - 百度百科
研究表明，局部应用5% 咪喹莫特乳剂，通过皮肤全身吸收很少。 （1） 咪喹莫特每周3次 (星期一、三、五或二、四、六)，临睡前用药。 在医生指导下合理用药以发挥本品的最大疗效。 建议 …
Imiquimod | TLR7 Agonist | Imidazoquinoline compound - InvivoGen
Imiquimod (R837), an imidazoquinoline amine analog to guanosine, is an immune response modifier with potent indirect antiviral activity. It is an FDA-approved treatment for external …
用聚合物胶束选择性靶向肿瘤相关的巨噬细胞和肿瘤细胞，以增强 …
肿瘤相关巨噬细胞（TAM）相关的免疫疗法是一种非常有前途的策略，其中涉及用免疫调节剂咪喹莫特（R837）改变免疫抑制性肿瘤微环境以增强癌症治疗。 然而，由于水溶性差和缺乏靶向 …